[Do benign prostatic hyperplasia drugs affect mood or cognition?]

Area of Science:

• Neurology
• Pharmacology
• Urology

Background:

• Lower urinary tract symptoms (LUTS) are commonly associated with benign prostatic hyperplasia (BPH).
• Pharmacological treatments for BPH include muscarinic antagonists and 5α-reductase inhibitors.
• Central nervous system (CNS) side effects are a potential concern with these medications.

Purpose of the Study:

• To review and discuss the risk of CNS side effects, specifically cognitive impairment/dementia and depressive symptoms.
• To evaluate the evidence linking BPH medications to these neurological adverse events.
• To inform clinicians about potential risks associated with LUTS treatments.

Main Methods:

• Review of current scientific evidence and published studies.
• Analysis of reported associations between BPH drug classes and CNS side effects.
• Assessment of mechanistic plausibility and potential confounding factors.

Main Results:

• Cognitive impairments are well-documented with muscarinic antagonists, with quantitative differences among agents.
• Depressive symptoms have been consistently observed with 5α-reductase inhibitors (dutasteride and finasteride).
• A single study suggested a possible link between tamsulosin and dementia, but this requires further investigation and may be due to bias.

Conclusions:

• Physicians should maintain awareness of potential CNS side effects during BPH pharmacotherapy.
• Cognitive and mood changes may necessitate medication review or adjustment.
• Further research is needed to fully elucidate the CNS risks associated with specific BPH drugs.